How about Shenwan Lingxin Pharmaceutical Pioneer Stock?
Shenwan Lingxin Pharmaceutical Pioneer Stock Fund is still in the subscription period. As a new fund, there is no historical income data, but combined with its investment strategy, fund manager's past performance and risk-return characteristics, we can understand this fund.
1 Risk-return characteristics: This fund is a stock fund, and its expected return and expected risk level are higher than those of hybrid funds, bond funds and money market funds. If the Fund invests in Hong Kong-listed stocks, it must bear the unique risks brought by the differences in investment environment, investment targets, market system and trading rules under the mechanism of Hong Kong-listed stocks.
(2) Investment strategy: The Fund will pay attention to the development trend of medical science and technology progress and medical level improvement in the whole society, and combine the competitive pattern, technological progress and product optimization characteristics of the medical and health industry to capture the relevant investment opportunities under the new medical consumption consciousness, consumption pattern and consumption trend, and grasp the investment opportunities in the medical and health industry under the general trend of scientific and technological progress; Through the combination of top-down industry allocation strategy and bottom-up stock selection strategy, we will choose the subdivided advantageous fields, outstanding companies with core competitive advantages and outstanding contribution enterprises leading the industry progress in the pharmaceutical theme-related industries, and strive to obtain stable excess returns.
3 Fund Manager: Ms. Sun Lin, Bachelor of Economics. He is currently the fund manager of Shenwan Lingxin Competitive Advantage Stock Securities Investment Fund. On June 24, 2020, he served as the fund manager of Shenwan Lingxin's consumption growth hybrid securities investment fund. 20 141From October 28th to July 28th, 2020, he served as the fund manager of Shenwan Lingxin Competitive Advantage Hybrid Securities Investment Fund.